Bavarian Nordic A/S (0DPB)
London Exchange · UK · prices in DKK · close of 22 Oct 2026
Key indicators
| Last close | DKK 241.80 |
|---|---|
| 52-week range | 171.60 – 244.10 |
| Return, 1 month / 3 months | +12.8% / +33.8% |
| Return, 1 year / 3 years | +5.0% / +84.1% |
| Trend | Uptrend |
| RSI (14) | 69 |
| Volatility (1 year) | 119.3% |
| Worst drawdown (1 year) | -28.3% |
| Average daily value traded | 3.09M DKK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bavarian Nordic is a vaccine company based in Denmark. It develops and manufactures vaccines for infectious diseases, including a smallpox and monkeypox vaccine supplied to governments and public health authorities. The company also provides contract manufacturing services, producing vaccines on behalf of other pharmaceutical firms. Its customers are mainly government agencies, public health bodies and healthcare organisations that stockpile or distribute vaccines, and its work spans research, clinical development and commercial production at its own facilities.
The shares are listed on the London Exchange in UK under the code 0DPB, and the price on this page is in Danish kroner (DKK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bavarian Nordic A/S (0DPB) trades on the London Exchange in UK. It last closed at DKK 241.80 on 22 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 1,190 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 5.0% and over the last three months it rose 33.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 20.3% | ||
| From 52-week high | -0.9% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 33.8% | ||
| 6-month return | 24.6% | ||
| 12-month return, skipping the last month | -6.9% | ||
| Stability (higher is calmer) | 28 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 119.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.3% | ||
| Liquidity | 63 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.09M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +1.2% |
|---|---|
| 1 month | +12.8% |
| 3 months | +33.8% |
| 6 months | +24.6% |
| 1 year | +5.0% |
| 3 years | +84.1% |
| 5 years | −23.0% |
Signals
| 50-day / 200-day average | 216.26 / 201.05 |
|---|---|
| Golden / death cross (60 days) | Golden, 14 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 21.38 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.